These days, Novo Nordisk is surrounded by an odd silence, the kind that typically descends upon a business that no one is discussing. The Danish pharmaceutical behemoth was the talk of the European markets a year ago, with its weight-loss medications influencing pop culture and Hollywood rumors.
Its shares are currently down about 36%, the CEO has been replaced, and it appears that investors have quietly left. You’ll hear the same discussion every time you pass an analyst desk in Copenhagen: has Eli Lilly truly made progress, or is the market overreacting to a single poor year?
| Company | Ticker | Market Cap | Sector / Note |
|---|---|---|---|
| Novo Nordisk | NVO | $154 billion | Danish pharmaceutical leader, GLP-1 pioneer |
| Vistra | NYSE: VST | $54 billion | Independent power producer, AI data-center exposure |
| Tesla | NASDAQ: TSLA | $1.5 trillion | Electric vehicles, robotaxi & humanoid robotics bets |
| Forward P/E (Novo) | ~13x | Below sector average | Considered unusually low for a large-cap pharma |
| Tesla forward P/E | ~197x | Premium valuation | Priced for future bets to materialize |
| Data as of | May 7, 2026 | Sourced from market filings | — |
The gloom is not quite matched by the fundamentals. The company is profitable, margins are still close to 33%, and Ozempic and Wegovy continue to disappear from pharmacy shelves at a rate that most pharmaceutical companies can only imagine. The company discreetly obtained approval for an oral weight-loss pill late last year, a milestone that would have caused the stock to soar in a different market climate. Rather, it hardly moved. The competition in GLP-1s is truly fierce, so it’s possible that investors are right to be wary, but at a forward P/E of roughly 13, the price already assumes a fair amount of disappointment. At a dinner party, the most intriguing purchases are sometimes the ones that no one wants to defend.
On the other end of the mood spectrum is Vistra. The energy that arises when a stock has tripled and everyone is constantly checking their screens to make sure it’s real must be a little different on its trading floors now. Power producers have benefited from the AI infrastructure boom, and Vistra has become somewhat of a Wall Street darling thanks to the expansion of its nuclear capacity following the acquisition of Energy Harbor. It makes sense. Electricity is necessary for hyperscalers, and they require a lot of it.
Even so, the math is beginning to seem awkward. Vistra is trading at a multiple that surpasses similar utilities, more than 15 times the management’s midpoint EBITDA target for 2025. Although the longer-term outlook is less clear, management suggests robust EBITDA growth through 2026, which is encouraging. Data center power demand is real, but it seems like investors should challenge the notion that it increases in a straight line more frequently than they do. History is not kind to stocks priced for permanent acceleration, and comparable companies trade for much less.
Then there’s Tesla, which is practically too well-known to discuss. It’s difficult to recall which version Wall Street is currently purchasing because the story has taken on so many different forms—first as an automaker, then as a robotaxi company, and finally as a humanoid robotics venture. In fact, revenue fell 3% in 2025, marking the first yearly decline in the business’s history. Deliveries fell by 8.6%. A quiet but significant tailwind was eliminated by the expiration of regulatory credits. The stock is currently trading at about 197 times this year’s projected earnings, and the market capitalization is still close to $1.5 trillion.
Perhaps the robotaxi rollout succeeds. Perhaps Optimus becomes the well-known brand Elon Musk claims. However, it’s difficult to ignore the discrepancy between what the main business is doing and what the share price anticipates will happen next as this develops. The danger lies in that gap. Additionally, the disparity seems worth considering in a year when Tesla is viewed as a generational platform and Novo Nordisk as a fading pharmacy chain.